Attached files
file | filename |
---|---|
8-K - 8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | pacb-20141023x8k.htm |
EX-99.2 - EX-99.2 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | pacb-20141023ex992c80620.htm |
EX-99.1 - EX-99.1 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | pacb-20141023ex9917efb7a.htm |
Exhibit 99.3
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Nine-Month Periods Ended September 30, |
|||||
(in thousands) |
2014 |
2013 |
|||
Cash flows from operating activities |
|||||
Net loss |
$ |
(47,185) |
$ |
(62,062) | |
Adjustments to reconcile net loss to net cash used in operating activities |
|||||
Depreciation |
3,311 | 4,238 | |||
Amortization of debt discount and financing costs |
579 | 418 | |||
Stock-based compensation |
6,944 | 7,361 | |||
Other |
242 | (73) | |||
Changes in assets and liabilities |
|||||
Accounts receivable |
376 | (992) | |||
Inventory |
(1,348) | 171 | |||
Prepaid expenses and other assets |
85 | 791 | |||
Accounts payable |
4,128 | 425 | |||
Accrued expenses |
821 | 544 | |||
Deferred service revenue |
1,661 | 56 | |||
Deferred contractual revenue |
(5,088) | 35,000 | |||
Other liabilities |
(637) | (1,136) | |||
Net cash used in operating activities |
(36,111) | (15,259) | |||
Cash flows from investing activities |
|||||
Purchase of property and equipment |
(1,132) | (807) | |||
Purchase of investments |
(97,468) | (141,549) | |||
Maturities of investments |
119,673 | 133,391 | |||
Net cash provided by (used in) investing activities |
21,073 | (8,965) | |||
Cash flows from financing activities |
|||||
Proceeds from issuance of common stock from equity plans |
3,319 | 2,731 | |||
Proceeds from issuance of common stock from at-the-market equity offering, net of issuance costs |
|
20,768 |
|
|
19,954 |
Proceeds from issuance of Facility Agreement, net of issuance costs |
— |
19,766 | |||
Net cash provided by financing activities |
24,087 | 42,451 | |||
Net increase in cash and cash equivalents |
9,049 | 18,227 | |||
Cash and cash equivalents at beginning of period |
26,362 | 46,540 | |||
Cash and cash equivalents at end of period |
$ |
35,411 |
$ |
64,767 | |